Real-world data from the Japanese National Health Insurance System enables fine phenotyping in a 14K-scale population-based study

Yayoi Otsuka-Yamasaki,[1,2,*] Naoyuki Nishiya,[1,3,*] Yoichi Sutoh,[1,2,*] Reiko Aoyama,[1] Kozo Tanno,[1,4] Motoki Nakao,[1,5,6] Shohei Komaki,[1,2] Shiori Minabe,[1,2] Hideki Ohmomo,[1,2] Koichi Asahi,[1,7] Yasushi Ishigaki,[1,8] Makoto Sasaki[1,9] and Atsushi Shimizu[1,2,†]

[1]Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[2]Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[3]Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[4]Department of Hygiene and Preventive Medicine, School of Medicine, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[5]Department of Pharmacology, School of Medicine, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[6]Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of

Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan

[7]Division of Nephrology and Hypertension, Department of Internal Medicine, School of

Medicine, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[8]Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine,

School of Medicine, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[9]Division of Ultrahigh field MRI, Institute for Biomedical Sciences, Iwate Medical University,

1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan.

*These authors contributed equally to this work

[†]Correspondence: ashimizu@iwate-med.ac.jp

Abstract

The use of medical databases, known as real-world data (RWD), facilitates accurate,

efficient, and frequent estimation of disease prevalence in population-based studies. Thus, it

is expected to be a game-changer in epidemiology and public health research. However, the

lack of standardized data formats across hospitals makes it challenging to integrate data

across institutions. In contrast, health insurance claims data in Japan are standardized under

a nationally unified format, making them a reliable source of structured RWD.

We aimed to evaluate the utility of insurance claims data in epidemiological research.

Incorporating both diagnosis and prescription information from claims into case definitions

resulted in four- and six-fold increases in the estimated prevalence of Alzheimer's disease (AD)

and Parkinson's disease, respectively, compared to conventional definitions based on self-

administered questionnaires. Subsequent genome-wide association studies (GWAS) for AD

demonstrated an increased log-likelihood of the model and identified a characteristic signal

at the *APOE* locus. These changes were exclusively observed when using claims-enriched case

definitions. The effect size of the *APOE* variant was further compared with previous GWAS

findings. Our results were consistent with case–control studies involving over 4,000 cases,

while the standard error remained comparable to that of smaller studies. These findings

suggest that incorporating claims-based clinical data—diagnoses and prescriptions—into

phenotype definitions improves case identification while maintaining accuracy. This approach

may support scalable strategies in genomic epidemiology and public health surveillance.

Keywords: Real-world data, Health insurance claims data, Genome-wide association studies,

Alzheimer's disease, Phenotyping

Introduction

The accurate estimation of disease prevalence within a community is crucial in public health. However, challenges remain. Recent advances in medical databases—such as electronic health records (EHRs) and health insurance claims data, collectively referred to as real-world data (RWD)—provide opportunities to enhance the accuracy, efficiency, and frequency of prevalence estimation in population-based studies. These developments also enable the scale-up of surveys and inform public health decision-making.[1,2] Furthermore, the integration of RWD with large-scale genome cohorts increasingly contributes to the generation of epidemiological evidence that informs genomic research.[3] Nonetheless, technical challenges remain. Although diagnoses recorded in EHRs are generally reliable, the lack of standardized data formats across hospitals in many regions limit the integration of data across institutions.[4]

Insurance claims data offer a standardized format that facilitates integration across institutions, particularly in countries with universal health coverage, such as Japan. In Japan, national health insurance claims are standardized across diverse healthcare providers and administered by local governments.[5] The Japanese health insurance system consists of two major schemes: the National Health Insurance (NHI), which covers individuals aged ≤74 years who are not enrolled in employee insurance, and the Late-stage Medical Care System for the Elderly (LsMCSE), which covers individuals aged ≥75 years.[6] Individuals are typically insured through their local municipal governments. Both systems provide structured diagnostic and prescription claims data, consequently enabling the retrieval and integration of health data from multiple regions under appropriate legal and ethical frameworks.[7]

The Tohoku Medical Megabank Community Cohort (TMM CommCohort) is a large-scale population-based cohort study established to monitor public health in areas affected by the 2011 Great East Japan Earthquake.[8] This cohort obtained health insurance claims data through agreements with participating local governments. In this context, diagnosis and

prescription data from claims can supplement medical histories based on self-administered

questionnaires (SAQs) and serve as proxies for clinical diagnoses.

In this study, we evaluated the incorporation of prescription and diagnosis data from

insurance claims into conventional case/control diagnostic definitions. The prevalence of

hypertension, dyslipidemia, diabetes, Parkinson's disease (PD), and Alzheimer's disease (AD)

is expected to increase in aging societies. Therefore, we aimed to evaluate whether

incorporating diagnosis and prescription data from insurance claims could improve

case/control definitions for these common diseases. We further sought to evaluate the accuracy

of phenotyping using claims-enriched case definitions in the context of genome-wide

association studies (GWAS). These findings may contribute to more scalable strategies in

genomic epidemiology and public health research. In addition, they highlight the potential

value of a feedback cycle in which claims data inform both public health action and evidence-

based policy development for insured individuals.

Materials and Methods

Population

The design of the TMM CommCohort study was described previously.[8] In the present study, we included participants from the TMM CommCohort study who held insurance from the NHI or LsMCSE and resided in Iwate Prefecture. Individuals with missing genotypic, phenotypic, and claims data, or other data necessary for analysis, were excluded from the study.

Participants were recruited during specific health checkups or through visits to cohort assessment centers between May 2013 and March 2016. Medical history (e.g., hypertension, dyslipidemia, diabetes, AD, and PD diagnoses) and treatment status for selected conditions (hypertension, dyslipidemia, and diabetes) were collected using SAQ. Systolic and diastolic blood pressure were measured twice at recruitment, and the average was used for analysis. Hemoglobin A1c (HbA1c), high- (HDL) and low-density lipoprotein (LDL) cholesterol, and triglyceride levels were measured in blood samples collected at recruitment.

National health insurance claims data, including medical, pharmacy, and Diagnosis Procedure Combination (DPC) receipts, were collected annually by electronically collating with participant information from the TMM CommCohort study in Iwate. This process enabled the construction of a claims-based dataset for TMM participants in Iwate. Personal identifiable information and non-research related elements were excluded to ensure strict data minimization and privacy protection. The claims data are structured in a standard format defined by the Japanese National Health Insurance System. Clinical endpoints were defined by a combination of disease and medication.

This study adhered to the principles of the Declaration of Helsinki, and written informed consent was obtained from all participants. All individual data were anonymized

127 before analysis. The study was approved by the Institutional Review Board of Iwate Medical

128 University (Approval number HG H25-2). Analyses involving personal genotypic or

129 phenotypic information were performed on a standalone computing system—the Tohoku

130 University Tohoku Medical Megabank Organization supercomputer.

Genotyping and GWAS

Genotyping and genotype imputation were performed as previously described.[9-11] In

the hard-call genotype data, variants that met any of the following criteria were excluded: low

call rate (<0.99), low heterozygous allele count (<5), deviation from Hardy–Weinberg

equilibrium ($p < 1\times 10^{-6}$), low minor allele frequency (<0.01), or location within regions of

strong linkage disequilibrium (LD).[12] Variant filtering was conducted using PLINK v1.9

(version b5.1).[13] LD pruning was performed with PLINK v2.0 (version a3LM) using the option

"--indep-pairwise 1500 150 0.03".

Principal component analysis (PCA) was conducted in PLINK v2.0 using the "--pca

approx allele-wts" option. One individual from each kinship pair (kinship > 0.0884) was

excluded based on the KING method to account for relatedness.[14] The resulting principal

components were then projected onto all individuals, including those excluded based on the

kinship threshold.

Case-control GWAS were conducted using SAIGE v0.44.6.5.[15] Individuals with a low

call rate (<0.99) or extreme genetic ancestry, defined as values of PC1 or PC2 deviating by ≥4

standard deviations from the mean, were excluded. In addition, imputed variants with low

imputation quality ($R^2 < 0.3$) or allele frequency (<0.01) were excluded from the analysis.

Statistical analysis

149   Statistical analyses were performed using R versions 4.1.0 and 4.3.2. Meta-analysis

150 was performed with the R package "meta" (version 8.0-2).[16]

Results

Retrieval of health insurance claims data and phenotyping

154   A workflow of the study is shown in Figure 1.

Figure 1. The workflow in this study.

The study participants had hard-called and imputed genotype data, as well as cohort

information including health insurance claims, demographic characteristics (age and sex),

laboratory test results, and responses to pre-specified items in a self-administered

questionnaire (SAQ). The RWD used in this study included disease diagnoses and

prescription histories derived from medical, pharmacy, and DPC claims data. Phenotyping

was performed using either conventional definitions based on SAQs and laboratory tests or

expanded definitions incorporating insurance claims data. HWE, Hardy-Weinberg

equilibrium; LD, linkage disequilibrium; MAF, minor allele frequency; PC, principal

component; V, variants.

Health insurance claims data on diagnosis and drug prescriptions were obtained for

19,880 individuals (7,638 men and 12,242 women) (Figure 1). Of these, 14,241 participants

met the cohort information and genotype data requirements. Claims data for hypertension,

diabetes, and dyslipidemia were retrieved from the NHI system and covered the period

between June 2013 and December 2019. The claims data for AD and PD were collected

between June 2013 and December 2020 and included data from both the NHI and LsMCSE.

Participants were classified into case and control groups using two criteria: (1) the

conventional case definition based on SAQs and laboratory tests used in the cohort study, and

(2) an expanded definition incorporating both disease names recorded in claims and drug

prescription data, in addition to (1) (Table 1).

Table 1. Case definition and prescription drugs for target outcomes.

Phenotype	Conventional case definition	Prescription drugs
Hypertension	SAQ (medical history or treatment status[a]) or SBP ≥ 140 mmHg or DBP ≥ 90 mmHg (JSH2019)[b]	Calcium antagonists, angiotensin II receptor blockers, diuretics, alpha blockers / beta blockers, angiotensin-converting-enzyme inhibitors, circulatory system hormones

Diabetes	SAQ (medical history or treatment status[a]) or HbA1c ≥ 6.5% (NGSP)[c]	Dipeptidyl peptidase-4 inhibitors, sulfonylureas, biguanide
		α-glucosidase inhibitors, insulin preparations, thiazolidine (TZD) derivative (pioglitazone hydrochloride), glinides, sodium glucose transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists
Dyslipidemia	SAQ (medical history or treatment status[a]) or HDL < 40 mg/dL or triglyceride ≥ 150 mg/dL or LDL ≥ 140 mg/dL[d]	HMG-CoA reductase inhibitors, fibrates
		Ezetimibe, polyunsaturated fatty acids, nicotinates, anion exchange resins, probucol
Alzheimer's disease, (Dementia)	SAQ (medical history)	Donepezil hydrochloride
		Galantamine hydrobromide
		Rivastigmine
		Memantine hydrochloride
Parkinson's disease,	SAQ (medical history)	Anticholinergics
		Dopamine receptor agonists / dopamine release enhancer (amantadine hydrochloride)
		Levodopa-containing agents / levodopa activator (zonisamide)

	Monoamine oxidase inhibitors
	Catechol-O-methyltransferase inhibitor (entacapone)
	Noradrenaline precursor (doroxidopa)
	Adenosine A2A receptor antagonist (istradefylline)

a) The response to the question regarding whether the participant was under treatment was used only for the conventional case definition, which did not incorporate prescription data.

b) Based on the Guidelines for the Management of Hypertension 2019 (JSH2019).

c) Defined according to the standards of the National Glycohemoglobin Standardization Program (NGSP).

d) Diagnostic criteria for arteriosclerosis, as defined by the Japan Atherosclerosis Society (2022).

SAQ, self-administered questionnaire; SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb, hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

The incorporation of claims data into phenotyping increased the prevalence of all target outcomes by 1.0–6.3% (Table 2). Common lifestyle-related diseases such as hypertension, diabetes, and dyslipidemia showed modest increases of 4.0%, 1.0%, and 6.3%, respectively. In contrast, the prevalence of AD and PD increased by more than six- and four-fold, respectively.

Table 2. Characteristics and prevalence by phenotype.

	Conventional case definition	+claims data
N (GWAS)	14,241[a]	
Female (%)	61.5	
Age	61.9 +/- 10.0	
Hypertension (% (n))	46.7 (6,644)	50.6 (7,211)
Diabetes (% (n))	11.2 (1,599)	12.2 (1,740)
Dyslipidemia (% (n))	53.6 (7,362)	59.9 (8,531)
Alzheimer's disease (% (n))	0.2 (22)	1.3 (183)
Parkinson's disease (% (n))	0.2 (34)	0.7 (106)

a) One participant was missing in the analysis of Alzheimer's disease, Parkinson's disease, and dyslipidemia.

GWAS

The effects of different phenotyping methods on GWAS results were confirmed (Figure 2A).

Figure 2. Genome-wide association studies (GWAS) using two case definitions.

GWAS were performed using two different case definitions: (1) the conventional method based on self-administered questionnaires (SAQ) (light-colored Manhattan plot; most of the plot is hidden), and (2) the conventional method combined with claims data (dark-colored Manhattan plot) (A). Gene names near genome-wide significant variants are shown in italics; those identified only in the GWAS using definition (2) are shown in bold italics. The red and blue dashed horizontal lines indicate the thresholds for genome-wide significance ($p = 5 \times 10^{-8}$) and suggestive significance ($p = 5 \times 10^{-5}$), respectively. $\lambda c/\lambda p$ denote genomic inflation factors for the GWAS based on case definitions (1) and (2), respectively; 95% confidence intervals are shown in square brackets. Comparison of the sum of log-likelihoods

(log L) from GWAS summary statistics between the two case definitions (B). The number of

variants and sample sizes were identical between the two analyses. Effect sizes and

directions of significant variants identified in GWAS using the two different case definitions

were compared (C). Variants are color-coded by chromosome. Bars and points represent the

standard errors and mean of the beta values, respectively. The dotted line represents the

diagonal.

Several genome-wide significant signals ($p < 5 \times 10^{-8}$) were detected for hypertension,

dyslipidemia, diabetes, and AD (Supplementary Table 1). *ALDH2* and *KCNQ1* were identified

in the GWAS for hypertension and diabetes. Both genes have been reported for blood pressure

and HbA1c, respectively, in previous GWAS (Figure 2A).[17] Known lipid-associated loci such as

APOB, LPL, TRIB1, APOA5, LDLR, and *APOE* were replicated in the GWAS for dyslipidemia,

consistent with prior findings on LDL and HDL, total cholesterol, and triglyceride levels.[17] In

contrast, association signals at 5p13.3 and the motilin gene locus were detected only in the

GWAS using claims-enriched case definitions. These two genes have been detected in the LDL

cholesterol or triglyceride GWAS of the TMM CommCohort study, which included 67K

participants (Study ID: TGA000007, https://jmorp.megabank.tohoku.ac.jp/gwas-studies/) and

Asian populations.[18,19,20] The lead variant rs4704208 in the 5p13.3 region identified in this

study is an expression quantitative trait locus for the HMGCR gene (Supplementary Table 1),

as determined according to the GTEx database (https://www.gtexportal.org/home/). This

enzyme is the pharmacological target of statins, which are widely prescribed for the treatment

of dyslipidemia.

The GWAS for AD using claims-enriched case definitions revealed significant signals

in *APOE*, whereas these signals were not detected in the GWAS based on conventional

phenotyping. The log-likelihood values, which indicate model fit, increased with the use of

claims-enriched phenotyping for AD (Figure 2B). The effect sizes and directions of significant

variants were consistent across the different phenotyping definitions (Figure 2C). The

standard errors of effect size estimates were smaller for AD when using the claims-enriched

case definition, indicating improved estimation precision.

Comparison with previous studies

The rs429358 C allele, a missense variant in *APOE* that results in a cysteine-to-

arginine substitution, is classified as a risk and/or pathogenic allele for AD (ClinVar accession:

VCV000017864.36). This variant was replicated in the present GWAS for AD (Figure 2). In

total, 976 studies reported rs429358-associated hits in the GWAS catalog.[21] Of these, seven

that reported associations with AD (Supplementary Table 1), mostly based on clinically

diagnosed cases using established guidelines, were comparable to the present study (Figure

3).

The odds ratio estimated in our study was 3.30 (95% CI: 2.26–4.82). This is consistent

with estimates from larger-scale studies (number of cases > 4000; 3.21 (3.02–3.41) reported

by Moreno-Grau et al.[22] and Wang et al.[23] (3.25 (2.94–3.58) and 3.66 (3.37–3.97)) (Figure 3A,

B). Moreover, the precision in our study was similar to that in studies with smaller cases

(number of cases < 500), such as those by Nazarian et al.[24] and Hong et al.[25] (Figure 3C).

Egger's test revealed a significant asymmetry (-3.49 ± 1.52; p = 0.0484) in the effect size

estimates of these GWAS.

Figure 3. Comparison with previous results.

Effect sizes of rs429358 were compared with those reported in previous studies registered in the GWAS Catalog (A). Studies associated with the trait "Alzheimer's disease" were selected. The effect size for each cohort (or subgroup) was used when available for analysis. The study design is indicated by color: magenta for population-based studies, black for case-control studies, and cyan for other designs (including meta-analyses and family-based studies). A funnel plot (B) and Egger's test (C) were used to assess potential publication bias. The linear regression test for funnel plot asymmetry yielded an intercept of -3.49 ± 1.52 (p = 0.0484). HRS, University of Michigan Health and Retirement Study; CHS, Cardiovascular Health Study; LOADFS, Late-Onset Alzheimer's Disease Family Study.

Discussion

According to the NIA-AA research framework,[26] a biological definition of AD requires costly and time-consuming assessments, such as biomarker testing using positron emission tomography or cerebrospinal fluid analysis. However, increasing case numbers and frequency of follow-up limit the practical application of these approaches. The more than six-fold increase in the estimated prevalence of AD demonstrates the effectiveness of RWD-based phenotyping in community-based cohort studies.

In the present study, the estimated prevalence of AD in the cohort was 1.3%. By 2025, the prevalence of dementia is estimated to be 1.10% (95% CI: 1.07–1.17) in men and 3.47% (95% CI: 3.41–3.52) among women aged 60–74 years in Japan.[27] As women comprised 61.5% of our dataset, the expected overall prevalence of dementia was approximately 2.56%, calculated as $0.615 \times 0.0347 + 0.386 \times 0.011$. Assuming that AD accounts for approximately two-thirds of all dementia cases in Japan,[28,29] its estimated prevalence would be approximately 1.7%, resulting in a smaller gap with the estimate derived using RWD. However, our dataset included claims data from the LsMCSE, thereby covering individuals aged 75 years and older. Because the prevalence of AD increases substantially with age[27]— especially among individuals aged ≥75—the inclusion of older adults may increase the overall prevalence. Nevertheless, given that the participants were followed up for 7 years, and most of the cohort remained under 75 years old, the observed prevalence of 1.3% may still represent a reasonable estimate.

Case/control classification based on RWD also affected the GWAS results for AD. The increased log-likelihood values suggest that this updated phenotyping approach may reduce the effect of unmeasured confounders that are not included in the regression models. The replicated detection of the *APOE* variant rs429358, which has been identified as an AD risk allele in several studies, further supports the validity of this approach. The odds ratio estimated in the present study was similar to those reported in large-scale clinical or meta-

analytic GWAS with more than 4,000 cases. However, the standard error remained

comparable to those from studies with similar case numbers. These findings suggest that the

revised case definition improved case identification while maintaining accuracy.

The prevalence of PD also increased when claims data were included. However, no

significant improvement was observed in the GWAS results. Although a few studies have

reported the prevalence of PD in Japan, regional estimates for East Asia suggested an all-age

prevalence of 0.357% (95% CI: 0.287–0.428) in 2021, which is estimated to increase to 0.821%

(95% CI: 0.674–0.995) by 2050.[30] The estimated prevalence of 0.7% in the present cohort,

which is predominantly older, is consistent with these projections.

A limitation of this study is the potential selection bias due to the characteristics of

the insured population. The claims data used in this study included data from the NHI system,

which covers approximately 30% of the Japanese population, and from the LsMCSE system

for those aged 75 years and older; therefore, it does not represent the entire population.[31]

Additionally, we could not directly compare the phenotypes estimated from prescription data

with clinical diagnoses made in hospitals. This was due to ethical constraints and the

substantial human effort required to collect diagnosis data from the hospitals where cohort

participants were treated. However, we plan to address this limitation in future research.

In conclusion, this study demonstrates that incorporating RWD into case definitions

can improve the efficiency of epidemiological research in population-based studies while

maintaining accuracy. These approaches may improve public health surveillance and

contribute to the advancement of precision medicine.

320   Data Availability Statement

The GWAS summaries have been published in jMorp

(https://jmorp.megabank.tohoku.ac.jp/gwas-studies/TGA000016). The datasets of individuals

in the TMM CommCohort study analyzed here are not publicly available owing to ethical

reasons, such as the protection of personal information and prevention of unintended personal

identification. However, they are accessible upon request, subject to approval from the Ethics

Committee of Iwate Medical University and the Materials and Information Distribution

Review Committee of the TMM Project. Those interested in obtaining the datasets for

individuals may contact the corresponding author.

References

1.   Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications,

challenges and opportunities. BMC Med Res Methodol. 2022;22:287.

https://doi.org/10.1186/s12874-022-01768-6.

2.   Swift B, Jain L, White C, Chandrasekaran V, Bhandari A, Hughes DA, *et al*.

Innovation at the intersection of clinical trials and real-world data science to

advance patient care. Clin Transl Sci. 2018;11:450–460.

https://doi.org/10.1111/cts.12559.

3.   Briggs SEW, Law P, East JE, Wordsworth S, Dunlop M, Houlston R, *et al*.

Integrating genome-wide polygenic risk scores and non-genetic risk to predict

colorectal cancer diagnosis using UK Biobank data: population based cohort study.

BMJ 2022;379:e071707. 10.1136/bmj-2022-071707.

4.   Hiramatsu K, Barrett A, Miyata Y, PhRMA Japan Medical Affairs Committee

Working Group 1. Current status, challenges, and future perspectives of real-world

data and real-world evidence in Japan. Drugs Real World Outcomes 2021;8:459–

480. https://doi.org/10.1007/s40801-021-00266-3.

5.   Shida H, Kajiyama K, Sawada S, Ishiguro C, Kubo M, Kimura R, *et al*. Use of

National Database of Health Insurance Claims and Specific Health Checkups for

examining practical utilization and safety signal of a drug to support regulatory assessment on postmarketing drug safety in Japan. Front Med (Lausanne) 2023;10:1096992. https://doi.org/10.3389/fmed.2023.1096992.

6. Ministry of Health, L.a.W. Overview of medical service regime in Japan. https://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken01/dl/01_eng.pdf. (Accessed 25 Sept 2025).

7. Fujinaga J, Fukuoka T. A review of research studies using data from the Administrative Claims Databases in Japan. Drugs Real World Outcomes 2022;9:543–550. https://doi.org/10.1007/s40801-022-00331-5.

8. Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N, *et al*. The Tohoku Medical Megabank Project: design and mission. J Epidemiol. 2016;26:493–511. https://doi.org/10.2188/jea.JE20150268.

9. Minegishi N, Nishijima I, Nobukuni T, Kudo H, Ishida N, Terakawa T, *et al*. Biobank establishment and sample management in the Tohoku Medical Megabank Project. Tohoku J Exp Med. 2019;248:45–55. https://doi.org/10.1620/tjem.248.45.

10. Sutoh Y, Hachiya T, Otsuka-Yamasaki Y, Komaki S, Minabe S, Ohmomo H, *et al*. Healthy lifestyle practice correlates with decreased obesity prevalence in individuals with high polygenic risk: TMM CommCohort study. J Hum Genet. 2025;70:9–15. https://doi.org/10.1038/s10038-024-01280-3.

11. Yasuda J, Kinoshita K, Katsuoka F, Danjoh I, Sakurai-Yageta M, Motoike IN, *et al*. Genome analyses for the Tohoku Medical Megabank Project towards establishment of personalized healthcare. J Biochem. 2019;165:139–158. https://doi.org/10.1093/jb/mvy096.

12. Price AL, Weale ME, Patterson N, Myers SR, Need AC, Shianna KV, *et al*. Long-range LD can confound genome scans in admixed populations. Am J Hum Genet.

2008;83:132–135; author reply 135–139. https://doi.org/10.1016/j.ajhg.2008.06.005.

13.   Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-

generation PLINK: rising to the challenge of larger and richer datasets.

Gigascience 2015;4:7. https://doi.org/10.1186/s13742-015-0047-8.

14.   Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust

relationship inference in genome-wide association studies. Bioinformatics

2010;26:2867–2873. https://doi.org/10.1093/bioinformatics/btq559.

15.   Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, *et al*.

Efficiently controlling for case-control imbalance and sample relatedness in large-

scale genetic association studies. Nat Genet. 2018;50:1335–1341.

https://doi.org/10.1038/s41588-018-0184-y.

16.   Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. Springer

International Publishing, Cham, 2015. https://doi.org/10.1007/978-3-319-21416-0.

17.   Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, *et al*. A cross-

population atlas of genetic associations for 220 human phenotypes. Nat Genet.

2021;53:1415–1424. https://doi.org/10.1038/s41588-021-00931-x.

18.   Chen CY, Chen TT, Feng YA, Yu M, Lin SC, Longchamps RJ, *et al*. Analysis across

Taiwan Biobank, Biobank Japan, and UK Biobank identifies hundreds of novel loci

for 36 quantitative traits. Cell Genom. 2023;3:100436.

https://doi.org/10.1016/j.xgen.2023.100436.

19.   Hsu LA, Teng MS, Duan DM, Yeh KH, Wu S, Ko YL. 3-Hydroxy-3-methylglutaryl-

CoA reductase variants strongly associated with low-density lipoprotein

cholesterol levels and diabetes mellitus risk in a Taiwanese population: A

Mendelian randomization study. Tzu Chi Med J. 2025;37:181–188.

https://doi.org/10.4103/tcmj.tcmj_247_24.

20.   Ismail Umlai UK, Toor SM, Al-Sarraj YA, Mohammed S, Al Hail MSH, Ullah E, *et*

al. A multi-ancestry genome-wide association study and evaluation of polygenic

scores of LDL-C levels. J Lipid Res. 2025;66:100752.

https://doi.org/10.1016/j.jlr.2025.100752.

21.   Cerezo M, Sollis E, Ji Y, Lewis E, Abid A, Bircan KO, *et al*. The NHGRI-EBI GWAS

Catalog: standards for reusability, sustainability and diversity. Nucleic Acids Res.

2025;53:D998–D1005. https://doi.org/10.1093/nar/gkae1070.

22.   Moreno-Grau S, de Rojas I, Hernandez I, Quintela I, Montrreal L, Alegret M, *et al*.

Genome-wide association analysis of dementia and its clinical endophenotypes

reveal novel loci associated with Alzheimer's disease and three causality networks:

The GR@ACE project. Alzheimers Dement. 2019;15:1333–1347.

https://doi.org/10.1016/j.jalz.2019.06.4950.

23.   Wang H, Lo MT, Rosenthal SB, Makowski C, Andreassen OA, Salem RM, *et al*.

Similar genetic architecture of Alzheimer's disease and differential APOE effect

between sexes. Front Aging Neurosci. 2021;13:674318.

https://doi.org/10.3389/fnagi.2021.674318.

24.   Nazarian A, Yashin AI, Kulminski AM. Genome-wide analysis of genetic

predisposition to Alzheimer's disease and related sex disparities. Alzheimers Res

Ther. 2019;11:5. https://doi.org/10.1186/s13195-018-0458-8.

25.   Hong S, Prokopenko D, Dobricic V, Kilpert F, Bos I, Vos SJB, *et al*. Genome-wide

association study of Alzheimer's disease CSF biomarkers in the EMIF-AD

Multimodal Biomarker Discovery dataset. Transl Psychiatry 2020;10:403.

https://doi.org/10.1038/s41398-020-01074-z.

26.   Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, *et al*.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's

423   disease. Alzheimers Dement. 2018;14:535–562.

424   https://doi.org/10.1016/j.jalz.2018.02.018.

425 27.   Kasajima M, Eggleston K, Kusaka S, Matsui H, Tanaka T, Son BK, *et al.* Projecting

426   prevalence of frailty and dementia and the economic cost of care in Japan from

427   2016 to 2043: a microsimulation modelling study. Lancet Public Health

428   2022;7:e458–e468. https://doi.org/10.1016/S2468-2667(22)00044-5.

429 28.   Ikeda S, Mimura M, Ikeda M, Wada-Isoe K, Azuma M, Inoue S, *et al.* Economic

430   burden of Alzheimer's disease dementia in Japan. J Alzheimers Dis. 2021;81:309–

431   319. https://doi.org/10.3233/JAD-210075.

432 29.   Montgomery W, Ueda K, Jorgensen M, Stathis S, Cheng Y, Nakamura T.

433   Epidemiology, associated burden, and current clinical practice for the diagnosis

434   and management of Alzheimer's disease in Japan. Clinicoecon Outcomes Res.

435   2018;10:13–28. https://doi.org/10.2147/CEOR.S146788.

436 30.   Su D, Cui Y, He C, Yin P, Bai R, Zhu J, *et al.* Projections for prevalence of

437   Parkinson's disease and its driving factors in 195 countries and territories to 2050:

438   modelling study of Global Burden of Disease Study 2021. BMJ 2025;388:e080952.

439   https://doi.org/10.1136/bmj-2024-080952.

440 31.   Shigeoka H. The effect of patient cost sharing on utilization, health, and risk

441   protection. Am Econ Rev. 2014;104:2152–2184.

443 ## Acknowledgements

444 This research utilized the supercomputer system and dbTMM provided by the Tohoku Medical

445 Megabank Project, supported by AMED under grant numbers JP21tm0424601 and

446 JP21tm0124005.

Author contributions

Conceptualization: Y.O-Y., Y.S., A.S.; Methodology: Y.O-Y., Y.S., A.S.; Investigation: N.N., R.A., K.T.; Formal analysis: Y.O-Y., N.N., Y.S.; Data curation: Y.O-Y., N.N., Y.S., K.T., A.S.; Writing—original draft: Y.O-Y., N.N., Y.S.; Writing—review & editing: Y.O-Y., N.N., Y.S., K.T., M.N., S.K., S.M., H.O., K.A., Y.I., M.S., A.S.

Funding

This study was supported by the Tohoku Medical Megabank (TMM) Project of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and by the Japan Agency for Medical Research and Development (AMED) under grant number JP23tm0124006, as well as by research funding from IQVIA. Y.O-Y. and A.S. were supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI under grant number 23K09696.

Ethical approval

This study was approved by the Institutional Review Board of Iwate Medical University (Approval number HG2021-009).

Declaration of interests

The authors declare no competing interests.

Declaration of generation AI and AI-assisted technologies in the writing process

During the preparation of this work the authors used ChatGPT 4o, including their Deep Research mode, in order to review and summarize previous papers and improve the computer script for analysis and the literature. After using this tool/service, the authors reviewed and

468 edited the content as needed and take full responsibility for the content of the publication.

Supplementary information

470 Supplemental_Table_1.xlsx. The Excel file includes Supplementary Table S1.